Skip to main content
Clinical Trials/NCT02472860
NCT02472860
Completed
N/A

Feasibility and Effectiveness of Computerized Cognitive Training in Adolescents With Autism Spectrum Disorder

Massachusetts General Hospital0 sites29 target enrollmentJune 2015

Overview

Phase
N/A
Intervention
Not specified
Conditions
Autism Spectrum Disorder
Sponsor
Massachusetts General Hospital
Enrollment
29
Primary Endpoint
Cambridge Neuropsychological Test Automated Battery (CANTAB)
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The investigators will conduct a randomized placebo-controlled trial of a computerized intervention targeting cognition in 30 teens with autism spectrum disorder.

Detailed Description

Given the limited options for treatments to improve the core symptoms of autism spectrum disorder (ASD), strategies that could target secondary features of the condition and improve quality of life for affected individuals are critical. Neuroplasticity-based cognitive training has been found to improve cognition in youth with attention deficit hyperactivity disorder (ADHD) and in adults with schizophrenia. In this trial, the investigators are seeking to extend the relevance of computerized cognitive training to youth with ASD. Given the literature, the investigators hypothesize that computerized cognitive training will produce gains in untrained cognitive tasks and behavioral ratings of executive functions in youth with ASD. The investigators will assess aspects of attention and executive functions in 30 affected youth and randomize them 1:1 to either neuroplasticity based cognitive tests or enjoyable age-appropriate computer games not intended to improve cognition. Cognition will be assessed again after 15 hours of training over 6 weeks and then again at a three month follow up.

Registry
clinicaltrials.gov
Start Date
June 2015
End Date
August 2, 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Alysa Emily Doyle, PhD

Assistant Professor of Psychiatry

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 ASD or previously diagnosed DSM-IV autistic disorder, Asperger's disorder or pervasive developmental disorder not otherwise specified (NOS) and who continue to manifest symptoms in core domains
  • Current ASD symptomatology at time of enrollment
  • Evidence of decrements in at least one of three target cognitive domains (mental flexibility/abstraction, working memory, or attention).

Exclusion Criteria

  • Intellectual Disability
  • A known comorbid neurodevelopmental disorder with possible association with autism (i.e., fragile X syndrome, tuberous sclerosis, Angelman syndrome, Prader-Willi syndrome, Williams syndrome, neurofibromatosis, mitochondrial disorder).
  • Nonverbal or minimal verbal ability
  • No computer/internet connection at home
  • No family member with e-mail
  • Patients likely to have a change in therapeutic treatments within the next 6 weeks

Outcomes

Primary Outcomes

Cambridge Neuropsychological Test Automated Battery (CANTAB)

Time Frame: 6 weeks

Computerized test

Similar Trials